Targeted Metabolic Alterations in Prostate Cancer: A Promising Therapeutic Strategy.

Area of Science:

• Oncology
• Cancer Metabolism
• Biochemistry

Background:

• Prostate cancer (PCa) treatment faces challenges due to resistance to current therapies like androgen receptor (AR)-targeted drugs and chemotherapy.
• PCa exhibits distinct metabolic phenotypes: early stages rely on oxidative phosphorylation (OXPHOS), while advanced stages utilize aerobic glycolysis (Warburg effect).

Purpose of the Study:

• To review the glucose metabolism characteristics of healthy, primary, and metastatic PCa cells.
• To explore therapeutic strategies targeting metabolic alterations in PCa.
• To discuss inhibitors targeting glycolysis, OXPHOS, and combined pathways for PCa treatment.

Main Methods:

• Literature review of metabolic pathways in prostate cancer.
• Analysis of glucose metabolism phenotypes in different PCa stages.
• Examination of inhibitors targeting key enzymes in glycolysis and OXPHOS.

Main Results:

• PCa cells exhibit a metabolic shift from OXPHOS to aerobic glycolysis as the disease progresses.
• Specific enzymes in glycolysis and OXPHOS are crucial for PCa cell survival and progression.
• Inhibitors targeting these metabolic pathways show potential for PCa therapy.

Conclusions:

• Understanding PCa's metabolic reprogramming is crucial for developing effective treatments.
• Targeting both glycolysis and OXPHOS may overcome resistance and improve therapeutic outcomes.
• Metabolic interventions represent a promising avenue for novel prostate cancer therapies.